论文部分内容阅读
临床上有20%～25%的非小细胞肺癌(NSCLC)患者可手术治疗,但5年生存率也只有40%左右。辅助化疗是部分早期可切除肺癌的标准治疗方式,可使4%～15%的患者生存获益。但是,ⅠB期NSCLC是否能从辅助化疗中获益仍存在争议。近年来,多个临床研究评价了ⅠB期NSCLC辅助化疗的疗效,我们通过分析这些临床研究,寻找ⅠB期NSCLC的高危人群和辅助化疗的适应证。
Clinically, 20% to 25% of patients with non-small cell lung cancer (NSCLC) can be treated surgically, but the 5-year survival rate is only about 40%. Adjuvant chemotherapy is the standard treatment for some of the early resectable lung cancers, which can benefit 4% to 15% of patients. However, whether stage Ⅰ B NSCLC can benefit from adjuvant chemotherapy remains controversial. In recent years, a number of clinical studies evaluated the efficacy of adjuvant chemotherapy for stage IB NSCLC. We analyzed these clinical studies to find indications for high-risk groups and adjuvant chemotherapy for stage IB NSCLC.